^
Association details:
Biomarker:FLT3-ITD mutation
Cancer:Acute Myelogenous Leukemia
Drug:AIU2008 (FLT3 inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Title:

Anti-leukemic Activity of AIU2008 in FLT3-ITD-positive Acute Myeloid Leukemia

Published date:
12/28/2020
Excerpt:
We evaluated the novel FLT3 inhibitor 5-(4-fluorophenyl)-N-(naphthalen-1-yl)oxazol-2-amine (AIU2008) for the treatment of AML...AIU2008 was designed by modifying FLT3 inhibitor 7c, and showed improved anti-leukemic efficacy in FLT3-ITD-positive AML cells. Specifically, AIU2008 inhibited cell growth and apoptotic death. In addition, AIU2008 down-regulated DNA repair genes involved in homologous recombination and non-homologous end joining. It contributed to the synergistic inhibition of AML cell growth in combination treatment with PARP inhibitors.
DOI:
10.21873/anticanres.14824